With just $3.5 million in cash on hand at June 30, 2026, FibroBiologics is running a tight clinical program, and the pressure on its upcoming interim data from CYWC628 could not be more concrete. The company has dosed its first patients in a Phase 1/2 trial evaluating CYWC628 for diabetic foot ulcers, a wound type that affects roughly 1.6 million Americans annually and that has proven stubbornly resistant to durable solutions despite decades of clinical effort. That proximity between a lean balance sheet and a pivotal readout is what makes the second half of 2026 a genuinely consequential period for this program.
CYWC628 is a fibroblast-spheroid cell-based therapy applied topically, and the trial design reflects a reasonable early-stage ambition: up to 120 patients in Australia, with endpoints covering safety, tolerability, and efficacy versus standard of care. Three cGMP manufacturing batches have been completed, two already released, which removes one of the logistical risks that stall early cell therapy programs before they gain momentum. The company targets interim results before year-end, with primary safety and efficacy data also expected by the close of 2026. That is an aggressive internal timeline, and it assumes enrollment proceeds without meaningful disruption.
The preclinical signal underpinning the broader fibroblast-spheroid platform deserves attention alongside the DFU news. Data presented this quarter showed that topical human dermal fibroblast spheroids appeared to reshape the burn wound environment within eight days, dampening inflammatory markers and reducing indicators of scar-forming activity. That kind of rapid immune reprogramming, if it translates to the clinic, would carry implications well beyond wound care. The company is simultaneously advancing CYPS317 toward an IND for psoriasis and CYMS101 toward an IND submission for multiple sclerosis, both targeted for Q4 2026. Whether those parallel programs are an asset or a distraction given the cash position is a question the interim CYWC628 data will largely answer.
The single variable that controls everything else here is the interim readout itself. A clean safety profile with any early efficacy signal in the diabetic foot ulcer population would justify the parallel IND strategy and likely unlock additional financing. Watch the proportion of patients completing the protocol without serious adverse events in that first interim cut, because that number sets the floor for every subsequent decision this company makes.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
